Chief Executive Officer and Chairman of the Board of Directors
Mark L. Baum is the founder, Chairman of the Board, and CEO of Harrow. For the 2014-2017 periods, Harrow (formerly Imprimis Pharmaceuticals) was named by Deloitte’s Technology Fast 500™ as one of the fastest growing companies in North America. Mr. Baum is also a founder of Eton Pharmaceuticals (NASDAQ: ETON) and Melt Pharmaceuticals, as well as a founder and board member of Surface Ophthalmics and Visionology. From 2014-2017, Mr. Baum was a senior advisor to VC-backed Prior to Harrow, as the founder of TBLF, LLC, a private investment fund manager, Mr. Baum made more than 200 investments into more than 40 private and public companies. In 1999, Mr. Baum founded YesRx, an HIV-focused pharmacy business. Mr. Baum’s advocacy for drug pricing and patient/physician accessibility issues has been featured in Op-Ed contributions for the Wall Street Journal and through appearances on CBS, CNN, MSNBC, Fox Business, Bloomberg and Al Jazeera. Mr. Baum was named by Ernst & Young LLP as the 2017 Entrepreneur of the Year™ in the life sciences category for the San Diego region. Mr. Baum is a graduate, cum laude, of The University of Texas at Arlington and a 1997 graduate of California Western School of Law.
Chief Financial Officer
Andrew R. Boll is one of the founding employees at Harrow. As Chief Financial Officer and Corporate Secretary, he oversees the Company’s financial and administrative operations. Mr. Boll has been integral in the evolution of Harrow, as a leader during the company’s initial start-up stage, to its NASDAQ listing, licensing and M&A activities and current commercial stage. Mr. Boll helped form and create Eton Pharmaceuticals, Surface Ophthalmics, Melt Pharmaceuticals, and ImprimisRx. Prior to Harrow, from 2007 to 2011, Mr. Boll worked for an investment company where he oversaw the fund’s accounting, financial analysis, and reporting; he was also heavily involved with the financial operations of a number of the fund’s portfolio companies (public and private). Prior to 2007, Mr. Boll held various accounting roles at Welsh Companies, LLC, a commercial real estate company, its fund and its other subsidiaries. Mr. Boll is a CFA® charterholder, Certified Management Accountant and earned his Bachelor of Science degree, summa cum laude, in Corporate and Public Finance.
Chief of Staff
KJ Barratt was named Chief of Staff to Harrow’s CEO, Mark L. Baum, in October 2023, after serving as Chief Talent Officer for Harrow since July 2022. Ms. Barratt is an accomplished operations leader with a 20-year record of driving higher profitability through a participative-management style of leadership that incorporates Six Sigma thinking, principles, and tools to achieve sustainable changes in process design, speed, cost, and quality. Prior to joining Harrow, Ms. Barratt worked for over six years with Novatech, a nationwide business technology provider, most recently as Chief Human Resources Officer responsible for all aspects of human resources, payroll and compensation, employee benefits and career mapping, recruitment and talent acquisition, employee law and policy compliance, company culture and community involvement. Prior to joining Novatech, she served in various leadership roles including Executive Vice President of Operations for Skyway Studies, Chief Resource Officer for Fort Campbell Federal Credit Union, and Manager, Learning and Development for Ingram Content Group. Ms. Barratt has a Master of Education degree in Human Resources Development from Vanderbilt University as well as a Master of Science in Leadership, Employment Law from Grand Canyon University.
Vice President of Legal and Compliance
Brett A. Burrell has served as Harrow’s Vice President of Legal and Compliance since October 2023. Mr. Burrell has over 25 years of experience as a healthcare attorney and has led compliance program efforts for companies in several industry segments including pharmaceuticals, hospitals, behavioral health, and toxicology. He has advised on a wide range of regulatory issues, including privacy, healthcare reimbursement, and pharmaceutical sales and marketing matters. Mr. Burrell obtained his law degree from the University of Memphis, his MBA from the University of Mississippi, and earned his Bachelor of Science degree, cum laude, in Accounting from Tennessee Technological University.
Chief Scientific Officer
Dennis E. Saadeh was named Harrow’s first Chief Scientific Officer in June 2023, after serving as Chief of Formulation Strategy since 2015. A pharmacist by education and training, he has 25 years of relevant drug development experience in a variety of settings. His current responsibilities include oversight of Harrow’s Medical and Clinical Affairs, Regulatory Affairs, CMC/Supply Chain Management for FDA-approved products, and Pharmacy Operations. Dr. Saadeh has been integrally involved in the development of the company’s portfolio of compounded formations and remains involved in pre-formulation and formulation development for a multitude of sterile drug product candidates. Additionally, he contributes and collaborates with the Harrow intellectual property team, analytical development group, active pharmaceutical ingredient suppliers and contract manufacturers to execute company initiatives. Prior to Harrow, from 1996 to 2015, Dr. Saadeh owned and operated a specialty pharmacy business focused on developing and dispensing customized compounded sterile and non-sterile preparations. Dr. Saadeh has his Doctor of Pharmacy degree from the University of Southern California and obtained his Fellowship in the American College of Apothecaries in 2005.
Chief Commercial Officer of Harrow
John P. Saharek is Chief Commercial Officer of Harrow and President and Chief Executive Officer of Harrow’s ImprimisRx Division. Mr. Saharek has over 30 years of broad experience developing and commercializing pharmaceutical, biologic, surgical device and diagnostic product portfolios. His results-oriented record of achievement includes designing and executing strategic commercial plans, building strong sustainable brands, launching new products and leading manufacturing, supply chain and quality operations. Over the past 20 years, he has been focused on the ophthalmic segment, where he has established valuable relationships with key opinion leaders and industry contacts. Prior to joining the Company in 2013, he served as Head of U.S. Marketing and Strategy for ThromboGenics, developing the commercial strategy and building a team to launch a new biologic into the U.S. market, and was Vice President, Business Development at SurModics, working with both large and small pharmaceutical companies on multi-platform drug delivery initiatives. Early on in his career, he held positions of increasing responsibility in both marketing and sales at a number of companies, including his tenure with Bausch & Lomb. Mr. Saharek has a Master of Business Administration from the University of Hartford and a bachelor’s degree from Central Connecticut State University.